NorthCrest Asset Manangement LLC Has $1.40 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

NorthCrest Asset Manangement LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 18.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,087 shares of the company’s stock after selling 4,210 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in AstraZeneca were worth $1,403,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Confluence Investment Management LLC acquired a new position in AstraZeneca during the first quarter worth about $27,000. Banque Transatlantique SA acquired a new position in AstraZeneca during the fourth quarter worth about $26,000. Mascagni Wealth Management Inc. acquired a new position in AstraZeneca during the fourth quarter worth about $29,000. CoreCap Advisors LLC raised its stake in AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after acquiring an additional 155 shares in the last quarter. Finally, Financial Management Professionals Inc. increased its stake in shares of AstraZeneca by 34.4% in the first quarter. Financial Management Professionals Inc. now owns 781 shares of the company’s stock valued at $57,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Separately, BNP Paribas assumed coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $85.00.

AstraZeneca Trading Down 0.8%

NASDAQ AZN opened at $74.42 on Friday. The firm has a market capitalization of $230.80 billion, a P/E ratio of 32.93, a PEG ratio of 1.42 and a beta of 0.38. The business has a fifty day simple moving average of $69.81 and a 200 day simple moving average of $70.29. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted $2.06 EPS. On average, analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.